A Philadelphia jury found Wednesday that the hormone replacement therapy drug Prempro was not the cause of two Pennsylvania women’s breast cancer.

The first Philadelphia hormone replacement therapy trial to group cases of multiple plaintiffs together for one trial was reverse bifurcated, and the plaintiffs attorneys first had to prove to the jury the causation of the plaintiffs’ breast cancer from their use of Prempro.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]